March 11, 2019 10:43 AM EDT

Is second time the charm for ozanimod? Celgene starts to find out with EMA filing

Amber Tong

Celgene has officially embarked on ozanimod’s comeback regulatory journey, submitting an application to the EMA days before it plans to knock on the FDA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Is second time the charm for ozanimod? Celgene starts to find out with EMA filing

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Versant unveils Light Horse with $62M and a partnership with Novartis

After lackluster 2024, biopharma industry prays stalled M&A will finally move into gear

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

IGM Biosciences’ autoimmune pivot lasts three months after interim data disappoint

Shoreline cuts staff as its partnership with Gilead's Kite is now in flux

Is sec­ond time the charm for ozan­i­mod? Cel­gene starts to find out with EMA fil­ing

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Is second time the charm for ozanimod? Celgene starts to find out with EMA filing